中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
16期
1031-1035
,共5页
罗辉燕%王玮%冯继红%罗治彬
囉輝燕%王瑋%馮繼紅%囉治彬
라휘연%왕위%풍계홍%라치빈
IGFBP5%胃腺癌%多因素分析%预后
IGFBP5%胃腺癌%多因素分析%預後
IGFBP5%위선암%다인소분석%예후
IGFBP5%gastric adenocarcinoma%multivariate analysis%prognosis
目的:探讨胰岛素样生长因子结合蛋白5(insulin-iike growth factor binding protein5,IGFBP5)在胃腺癌中的表达及临床意义。方法:应用免疫组织化学检测236例胃腺癌手术切除术后标本中IGFBP5的表达,并探讨其表达与患者临床病理参数的相关性及对于胃腺癌的预后意义。结果:免疫组织化学结果显示,236例患者中159例(67.4%)IGFBP5表达下调,且在肿瘤大小>5 cm、低分化胃腺癌、T3+T4a/b及Ⅲ/Ⅳ期胃癌患者中表达下调明显(P<0.05)。生存分析显示IGFBP5低表达患者预后较差(P<0.05)。多因素分析显示IGFBP5可作为一个独立预后风险因素(HR=1.897,P=0.029)。结论:胃腺癌中IGFBP5的表达下调,与进展期的临床病理参数相关,且提示预后不良。
目的:探討胰島素樣生長因子結閤蛋白5(insulin-iike growth factor binding protein5,IGFBP5)在胃腺癌中的錶達及臨床意義。方法:應用免疫組織化學檢測236例胃腺癌手術切除術後標本中IGFBP5的錶達,併探討其錶達與患者臨床病理參數的相關性及對于胃腺癌的預後意義。結果:免疫組織化學結果顯示,236例患者中159例(67.4%)IGFBP5錶達下調,且在腫瘤大小>5 cm、低分化胃腺癌、T3+T4a/b及Ⅲ/Ⅳ期胃癌患者中錶達下調明顯(P<0.05)。生存分析顯示IGFBP5低錶達患者預後較差(P<0.05)。多因素分析顯示IGFBP5可作為一箇獨立預後風險因素(HR=1.897,P=0.029)。結論:胃腺癌中IGFBP5的錶達下調,與進展期的臨床病理參數相關,且提示預後不良。
목적:탐토이도소양생장인자결합단백5(insulin-iike growth factor binding protein5,IGFBP5)재위선암중적표체급림상의의。방법:응용면역조직화학검측236례위선암수술절제술후표본중IGFBP5적표체,병탐토기표체여환자림상병리삼수적상관성급대우위선암적예후의의。결과:면역조직화학결과현시,236례환자중159례(67.4%)IGFBP5표체하조,차재종류대소>5 cm、저분화위선암、T3+T4a/b급Ⅲ/Ⅳ기위암환자중표체하조명현(P<0.05)。생존분석현시IGFBP5저표체환자예후교차(P<0.05)。다인소분석현시IGFBP5가작위일개독립예후풍험인소(HR=1.897,P=0.029)。결론:위선암중IGFBP5적표체하조,여진전기적림상병리삼수상관,차제시예후불량。
Objective: To investigate the expression and prognostic significance of insulin-like growth factor binding protein 5 (IGFBP5) in gastric adenocarcinoma (GAC). Methods:IGFBP5 expression in tissue samples from 236 GAC patients was analyzed us-ing immunohistochemical methods. These patients had undergone surgical resection between 20003 and 2006 in Sun Yat-Sen Universi-ty Cancer Center. The relationship between IGFBP5 expression and clinicopathological factors in the 236 GAC patients was analyzed using Pearson correlation analysis. The significance of IGFBP5 in predicting the survival status of these patients was analyzed using Ka-plan-Meier survival analysis and Cox's proportional hazards regression model. Results:Immunohistochemical staining data indicated that IGFBP5 expression was significantly decreased in 159 of the total GAC cases (67.4%). Of the 62 cases with well-and moderately differentiated GAC, 31 (50%) exhibited reduced IGFBP5 expression. Of the 174 cases with poorly differentiated GAC, 128 showed re-duced IGFBP5 expression. Reduced IGFBP5 expression was also observed in female patients and in patients with tumors over 5 cm in size or with poorly differentiated tumors (P<0.05). The reduced expression of IGFBP5 was common in the tumors that were staged as T3+4a/b andⅢ/Ⅳ(P<0.05). Kaplan-Meier survival analysis revealed that the reduced expression of IGFBP5 was associated with poor prognosis in GAC patients (P<0.001). Cox regression analysis identified IGFBP5 expression as an independent prognostic factor for the overall survival of these cancer patients (HR=1.897, P=0.029). Conclusion: IGFBP5 expression is reduced in GAC tissues, and IGFBP5 independently predicts an unfavorable prognosis in GAC patients.